Display search results for ** instead (17 products)

Showing 11-17 of 17

The market for regenerative medicine, one of the fastest growing segments in the biotechnology industry, is estimated to reach $67.5 billion by 2020 recording a compound annual growth rate (CAGR) of 22%. Current industry trends signal the expanding horizons of regenerative medicine, with its application being explored in new therapeutic segments su...

USD 1,500.00

USD 1,125.00 save 25 %

16 Nov 2016  |  Global

Innovations in the Global Orthopedic Devices Industry

Assessing the Innovations in Orthopedic Devices and Procedure Improvement Solutions that are set to Transform the Industry

The insight analyzes the innovations expected to play a major role in shaping the global orthopedic devices industry over the next few years. The demand for patient-specific implantation/surgeries is rising, along with the demand for better procedural efficiencies. This is becoming a driver for the emergence of new technologies. Therapies and proce...

USD 1,500.00

USD 1,125.00 save 25 %

08 Sep 2016  |  Global

Growth Opportunities for Healthcare Big Data—An Analysis of Global Case Studies

Big Data Initiatives Targeted at Health Prediction and Precision

The healthcare industry has been a laggard in Big Data adoption as compared to other verticals and continues to battle challenges around interoperability, budget constraints, and insufficient strategic planning and change management. However, the intent to leverage the power of Big Data is evident across all industry stakeholders, including governm...

USD 1,500.00

USD 1,125.00 save 25 %

This Vital Signs issue discusses the clinical diagnostics laboratory tests payment system, approval of a Zika test kit, the impact on innovation of mergers in the pharma/biotech industry, and national healthcare expenditure projections through 2025.

USD 600.00

USD 450.00 save 25 %

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Luminex's acquisition of Nanosphere, Medicare's changing approach to paying doctors, Orig3N's partnership with the San Francisco 49ers for collection of blood samples for research, and FDA's halt of Juno Therapeuticss cell therapy trial which left three dead.

USD 450.00

USD 337.50 save 25 %

This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.

USD 450.00

USD 337.50 save 25 %

Showing 11-17 of 17